Return to homepagePandemic Pact

Almitrine as a treatment for hypoxaemia in severe COVID-19 disease

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    LifeArc

  • Principal Investigator

    Unspecified Unspecified Unspecified

  • Research Location

    United Kingdom

  • Lead Research Institution

    University of Oxford

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The University of Oxford, in collaboration with clinicians in Wales and Berkshire and with funding from LifeArc, is set to commence clinical trials testing almitrine in COVID-19 patients at three UK hospitals. Almitrine is a drug that was developed in France to treat lung diseases like chronic obstructive pulmonary disease (COPD). Small scale trials have previously shown that it can improve oxygen saturation in patients with acute respiratory distress syndrome (ARDS) by redirecting blood flow within the lungs. Based on these findings, the drug will be tested in humans with COVID-19 to test its effectiveness.